FOCUS The Journal of Lifelong Learning in Psychiatry,
Journal Year:
2022,
Volume and Issue:
20(4), P. 358 - 367
Published: Oct. 1, 2022
Borderline
personality
disorder
is
a
complex
psychiatric
with
limited
treatment
options
that
are
associated
large
heterogeneity
in
response
and
high
rates
of
dropout.
New
or
complementary
treatments
for
borderline
needed
may
be
able
to
bolster
outcomes.
In
this
review,
the
authors
comment
on
plausibility
research
3,4-methylenedioxymethamphetamine
(MDMA)
used
conjunction
psychotherapy
(i.e.,
MDMA-assisted
[MDMA-AP]).
On
basis
promise
MDMA-AP
treating
disorders
overlapping
(e.g.,
posttraumatic
stress
disorder),
speculate
initial
targets
hypothesized
mechanisms
change
grounded
prior
literature
theory.
Initial
considerations
designing
clinical
trials
investigate
safety,
feasibility,
preliminary
effects
also
presented.
Nature Medicine,
Journal Year:
2023,
Volume and Issue:
29(8), P. 1947 - 1953
Published: July 24, 2023
Abstract
Anorexia
nervosa
(AN)
is
a
deadly
illness
with
no
proven
treatments
to
reverse
core
symptoms
and
medications
approved
by
the
US
Food
Drug
Administration.
Novel
are
urgently
needed
improve
clinical
outcomes.
In
this
open-label
feasibility
study,
10
adult
female
participants
(mean
body
mass
index
19.7
kg
m
−
2
;
s.d.
3.7)
who
met
Diagnostic
Statistical
Manual
of
Mental
Disorders
,
Fifth
Edition
(DSM-5)
criteria
for
AN
or
pAN
(partial
remission)
were
recruited
study
conducted
at
an
academic
research
institute.
Participants
received
single
25-mg
dose
synthetic
psilocybin
in
conjunction
psychological
support.
The
primary
aim
was
assess
safety,
tolerability
post-treatment
incidences
occurrences
adverse
events
(AEs)
clinically
significant
changes
electrocardiogram
(ECG),
laboratory
tests,
vital
signs
suicidality.
No
observed
ECG,
Two
developed
asymptomatic
hypoglycemia
post-treatment,
which
resolved
within
24
h.
other
values.
All
AEs
mild
transient
nature.
Participants’
qualitative
perceptions
suggest
that
treatment
acceptable
most
participants.
Results
therapy
safe,
tolerable
AN,
promising
finding
given
physiological
dangers
problems
engagement.
ClinicalTrials.gov
identifier
NCT04661514
.
International Journal of Eating Disorders,
Journal Year:
2023,
Volume and Issue:
56(6), P. 1055 - 1074
Published: March 14, 2023
Many
individuals
diagnosed
with
an
eating
disorder
(ED)
have
been
exposed
to
traumatic
events,
and
some
of
these
are
posttraumatic
stress
(PTSD).
Although
theorized
by
researchers
clinicians,
it
is
unclear
whether
event
exposure
or
PTSD
interferes
outcomes
from
ED
treatment.
The
objective
the
current
study
was
systematically
review
literature
on
events
and/or
as
either
predictors
moderators
psychological
treatment
in
EDs.
Journal of Eating Disorders,
Journal Year:
2023,
Volume and Issue:
11(1)
Published: March 27, 2023
We
studied
whether
provisional
posttraumatic
stress
disorder
(PTSD)
moderated
discharge
(DC)
and
6-month
follow-up
(FU)
outcomes
of
multi-modal,
integrated
eating
(ED)
residential
treatment
(RT)
based
upon
principles
cognitive
processing
therapy
(CPT).ED
patients
[N
=
609;
96%
female;
mean
age
(±
SD)
26.0
±
8.8
years;
22%
LGBTQ
+]
with
without
PTSD
completed
validated
assessments
at
admission
(ADM),
DC
FU
to
measure
severity
ED,
PTSD,
major
depressive
(MDD),
state-trait
anxiety
(STA)
symptoms,
quality
life
(EDQOL).
tested
the
course
symptom
change
using
mixed
models
analyses
if
ED
diagnosis,
ADM
BMI,
onset
+
orientation
were
significant
covariates
change.
Number
days
between
was
used
as
a
weighting
measure.Despite
sustained
improvements
RT
in
total
group,
group
had
significantly
higher
scores
on
all
measures
time
points
(p
≤
.001).
Patients
(n
261)
348)
showed
similar
from
remained
statistically
improved
compared
ADM.
The
only
worsening
observed
MDD
yet
lower
than
There
no
by
interactions
for
any
measures.
Age
covariate
EDI-2,
PHQ-9,
STAI-T,
EDQOL
such
that
an
earlier
associated
worse
outcome.
BMI
also
EDE-Q,
models,
outcome.Integrated
approaches
address
comorbidity
can
be
successfully
delivered
are
FU.
Improving
strategies
prevent
post-DC
recurrence
symptoms
is
important
challenging
area
future
work.Posttraumatic
common
disorders
outcomes.
However,
this
has
not
been
extensively
admitted
levels
care,
treatment.
Using
clinical
approach
(CPT)
other
evidence-based
treatments,
we
6
months
following
609
[96%
PTSD.
All
admission.
measured
including
those
disorder,
depression,
state
trait
anxiety,
life,
every
point
(admission,
discharge,
follow-up).
depression
follow-up.
In
conclusion,
related
problems
discharge.
post-discharge
work.
Frontiers in Psychiatry,
Journal Year:
2023,
Volume and Issue:
14
Published: May 12, 2023
Psychiatric
comorbidity
is
the
norm
in
assessment
and
treatment
of
eating
disorders
(EDs),
traumatic
events
lifetime
PTSD
are
often
major
drivers
these
challenging
complexities.
Given
that
trauma,
PTSD,
psychiatric
significantly
influence
ED
outcomes,
it
imperative
problems
be
appropriately
addressed
practice
guidelines.
The
presence
associated
noted
some
but
not
all
sets
existing
guidelines,
they
mostly
do
little
to
address
problem
other
than
referring
independent
guidelines
for
disorders.
This
disconnect
perpetuates
a
“silo
effect,”
which
each
set
complexity
comorbidities.
Although
there
several
published
EDs,
likewise,
none
them
specifically
+
PTSD.
result
lack
integration
between
providers,
leads
fragmented,
incomplete,
uncoordinated
ineffective
care
severely
ill
patients
with
situation
can
inadvertently
promote
chronicity
multimorbidity
may
particularly
relevant
treated
higher
levels
care,
where
prevalence
rates
concurrent
reach
as
high
50%
many
more
having
subthreshold
has
been
progress
recognition
recommendations
treating
this
common
remain
undeveloped,
when
co-occurring
disorders,
such
mood,
anxiety,
dissociative,
substance
use,
impulse
control,
obsessive–compulsive,
attention-deficit
hyperactivity,
personality
also
trauma-related.
In
commentary,
assessing
related
critically
reviewed.
An
integrated
principles
used
planning
trauma-related
recommended
context
intensive
therapy.
These
strategies
borrowed
from
evidence-based
approaches.
Evidence
suggests
continuing
traditional
single-disorder
focused,
sequential
models
prioritize
integrated,
trauma-focused
approaches
short-sighted
perpetuate
dangerous
multimorbidity.
Future
would
well
illness
depth.
European Neuropsychopharmacology,
Journal Year:
2023,
Volume and Issue:
75, P. 1 - 14
Published: June 21, 2023
Eating
disorders
are
serious
illnesses
showing
high
rates
of
mortality
and
comorbidity
with
other
mental
health
problems.
Psychedelic-assisted
therapy
has
recently
shown
potential
in
the
treatment
several
common
comorbidities
eating
disorders,
including
mood
post-traumatic
stress
disorder,
substance
use
disorders.
The
theorized
therapeutic
mechanisms
psychedelic-assisted
suggest
that
it
could
be
beneficial
as
well.
In
this
review,
we
summarize
preliminary
data
on
efficacy
people
anorexia
nervosa,
bulimia
binge
which
include
studies
case
reports
ketamine,
MDMA,
psilocybin,
ayahuasca.
We
then
discuss
these
three
both
general
those
relatively
specific
to
find
evidence
may
effective
nervosa
very
little
available
disorder.
Regarding
mechanisms,
able
improve
beliefs
about
body
image,
normalize
reward
processing,
promote
cognitive
flexibility,
facilitate
trauma
processing.
Just
importantly,
appears
factors
relevant
many
their
comorbidities.
Lastly,
safety
concerns
associated
treatments
present
recommendations
for
future
research.
Drug Science Policy and Law,
Journal Year:
2023,
Volume and Issue:
9
Published: Jan. 1, 2023
Although
there
is
a
growing
support
for
the
use
of
psychedelics
to
improve
health
marginalized
groups,
are
some
critical
gaps.
First,
no
empirical
studies
have
examined
effects
on
Black
Americans.
Second,
little
research
population
psychedelics.
Third,
has
tested
how
cultural
set
and
setting
may
affect
relationship
between
health.
Specifically,
could
economic
inequality
or
criminal
justice
system
jeopardize
people.
This
study
tests
race
gender
differences
in
multiple
aspects
lifetime
classic
psychedelic
use,
specifically
drug
arrest
history,
inequality,
psychological
distress.
project
uses
pooled
data
White
respondents
from
National
Survey
Drug
Use
Health
(2008–2019)
(
N
=
490,586).
The
analysis
includes
series
logistic
ordinary
least
square
regression
models
conducted
Stata
17.
Results
demonstrate
that
people
policed
more
even
though
they
less
drugs
than
Whites.
Higher
class
men
likely
psychedelics,
while
does
not
predict
among
Finally,
women,
positive
association
enhanced
by
class,
negative
effect
history
buffered
However,
do
gain
benefits
regardless
history.
suggest
systemic
deters
eliminates
all
Drug Science Policy and Law,
Journal Year:
2024,
Volume and Issue:
10
Published: Jan. 1, 2024
Although
there
is
a
growing
support
for
the
protective
factor
of
psychedelics
to
improve
mental
and
physical
health,
these
effects
may
differ
across
racial
ethnic
groups.
Race
differences
remain
critically
understudied
gap
in
psychedelic
literature.
Recent
empirical
research
into
Minority
Diminished
Psychedelic
Returns
suggests
that
Black
Americans
gain
little
health
benefits
from
use.
This
study
tests
race
association
between
Lifetime
Classic
Use
multiple
indicators
cardio-metabolic
including
cardiovascular
disease,
hypertension,
Body
Mass
Index.
project
uses
pooled
data
White
adults
respondents
National
Survey
Drug
Health
(NSDUH)
(2005
2019)
(N
=
421,477).
The
analysis
includes
series
logistic
ordinary
least
square
regression
models
conducted
Stata
18.
Results
demonstrate
associated
with
better
health.
However,
by
find
no
LCPU
cardio
metabolic
people,
while
positive
associations
significant
white
people.
Overall,
results
lend
MPDR
theory.
PLoS ONE,
Journal Year:
2024,
Volume and Issue:
19(3), P. e0293675 - e0293675
Published: March 7, 2024
Although
the
use
of
psychedelics
to
impact
health
has
seen
growth,
little
research
tested
effects
culture
conditions
on
relationship.
More
specifically,
how
does
marital
status
and
family
size
affect
relationship
between
health?
This
study
tests
Lifetime
Classic
Psychedelic
Use
(LCPU),
status,
household
(number
people
living
in
a
household)
levels
psychological
distress
past
30
days.
project
uses
pooled
data
from
National
Survey
Drug
Health
(NSDUH)
(2010
2018)
(
N
=
674,521).
The
Final
sample
is
determined
by
dependent
variable,
month
(n
158,633).
analysis
includes
series
nested
logistic
regression
models
conducted
Stata
17.
Results
indicate
that
LCPU
independently
associated
with
better
health,
but
association
varies
across
size.
Larger
households
are
higher
distress,
which
then
exacerbated
among
users.
Furthermore,
three-way
interactions
reveal
negative
gets
larger
psychedelic
users
who
married,
divorced,
widowed.
Overall,
results
suggest
negatively
impacts
those
widowed
experiencing
worst
outcomes.
Journal of Racial and Ethnic Health Disparities,
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 16, 2024
Abstract
Growing
evidence
suggests
that
the
race
and
ethnic
minority
population
may
experience
fewer
protective
effects
of
psychedelics
on
mental
health.
The
diminished
psychedelic
returns
theory
proposes
racism,
manifested
in
socioeconomic
inequality,
could
partially
account
for
smaller
health
gains
observed.
Therefore,
it
is
important
to
investigate
whether
inequality
reduces
impact
outcomes
populations.
Additionally,
despite
having
higher
status,
remains
unclear
use
among
minorities
associated
with
same
level
benefits
as
observed
non-Hispanic
whites.
This
study
utilizes
data
from
National
Survey
Drug
Use
(
N
=
2008
2019),
which
involved
458,372
participants
aged
18
above.
objective
examine
various
(MDMA,
psilocybin,
DMT,
ayahuasca,
peyote/mescaline,
LSD),
well
lifetime
classic
(LCPU),
psychological
distress
past
month,
taking
into
factors
(education
family
income)
race/ethnic
differences
(White,
Black,
Hispanic,
Asian).
analysis
employed
a
series
nested
ordinary
least-square
regression
models
using
Stata
18.
results
indicate
that,
after
controlling
there
no
association
between
Black
Hispanic
distress.
However,
white
lower
levels
education
income,
groups
does
not
appear
be
linked
reduced
stress.
In
fact,
Asians
certain
increased